Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBYCLOR vs AZILSARTAN MEDOXOMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Treatment of hypertension to lower blood pressure; lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Treatment of hypertension (FDA-approved),Off-label: heart failure, diabetic nephropathy
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
40 mg orally once daily. May increase to 80 mg once daily if needed.
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan; azilsartan is metabolized primarily by CYP2C9. Chlorthalidone is minimally metabolized, with most of the dose excreted unchanged in urine.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan.
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Azilsartan: >99% bound to serum albumin; chlorthalidone: approximately 75% bound to albumin and lipoproteins
High (>99%) to serum albumin.
Azilsartan: approximately 16 L (0.2 L/kg) indicating limited extravascular distribution; chlorthalidone: approximately 3-4 L/kg (extensive tissue binding, particularly to erythrocytes)
Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution.
Azilsartan medoxomil: absolute bioavailability approximately 60% (oral); chlorthalidone: approximately 65% (oral)
Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans.
e GFR <30 m L/min/1.73m2: not recommended. No adjustment required for e GFR ≥30 m L/min/1.73m2.
No dose adjustment required for GFR ≥15 m L/min/1.73 m². Not recommended for GFR <15 m L/min/1.73 m² due to lack of data.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): contraindicated. Child-Pugh Class C (severe): contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for use in pediatric patients (safety and efficacy not established).
Initiate with the lowest available dose (40 mg/12.5 mg) and titrate cautiously due to increased risk of hypotension and electrolyte disturbances.
No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity.
None
none
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause oligohydramnios, fetal renal dysfunction, and neonatal hypotension, hyperkalemia, and skull hypoplasia. Discontinue Edarbyclor as soon as possible when pregnancy is detected.,Hypotension: Correct volume- or salt-depleted patients prior to initiation; monitor for symptomatic hypotension.,Electrolyte disturbances: Chlorthalidone may cause hypokalemia, hyponatremia, and hypomagnesemia. Monitor electrolytes periodically.,Renal function deterioration: Monitor renal function in patients with renal artery stenosis, severe heart failure, or volume depletion.,Hyperkalemia: Risk increased with renal impairment, diabetes, or concomitant use of potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium.,Acute angle-closure glaucoma: Chlorthalidone, as a sulfonamide derivative, can cause idiosyncratic reaction leading to acute transient myopia and acute angle-closure glaucoma.,Exacerbation of systemic lupus erythematosus: Chlorthalidone may exacerbate or activate SLE.,Metabolic: Chlorthalidone may increase serum glucose, uric acid (precipitating gout), and decrease urinary calcium excretion.,Sulfonamide allergy: Chlorthalidone is a sulfonamide derivative; caution in patients with sulfonamide allergy.
Fetal toxicity: avoid use in pregnancy,Hypotension in volume-depleted patients,Renal impairment: monitor renal function,Hyperkalemia: monitor potassium levels
Anuria,Hypersensitivity to azilsartan medoxomil, chlorthalidone, or any component of the formulation,Concomitant use with aliskiren in patients with diabetes mellitus
Pregnancy (second and third trimesters),Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min)
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, salt substitutes) in excess due to risk of hyperkalemia. Avoid excessive salt intake. Grapefruit juice may alter drug metabolism; limit or avoid consumption. Alcohol may potentiate hypotensive effects.
No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness.
First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the second and third trimesters. There is no known risk of major malformations with first trimester exposure, but data are limited. Second and third trimesters: Use is contraindicated due to fetal renal dysfunction, oligohydramnios, pulmonary hypoplasia, limb contractures, and neonatal anuria, hypotension, and death. Azilsartan medoxomil (ARB) and chlorthalidone (thiazide diuretic) both affect RAS and fetal hemodynamics.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death.
No data on azilsartan medoxomil or chlorthalidone presence in human milk, effects on the breastfed infant, or milk production. Chlorthalidone is present in breast milk at low levels; M/P ratio unknown. Due to potential for adverse effects in the nursing infant (e.g., hypotension, renal impairment), alternative agents are recommended.
No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown.
EDARBYCLOR is not recommended in pregnancy, especially during second and third trimesters; if exposure occurs, discontinue as soon as possible. No specific dose adjustment studied; however, pregnancy can increase volume of distribution and clearance of some antihypertensives, but no data for this combination. Use is contraindicated after first trimester.
No dose adjustments during pregnancy; however, use is contraindicated in second and third trimesters due to fetal toxicity. If exposure occurs, discontinue as soon as possible.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil (an ARB) and chlorthalidone (a thiazide-like diuretic). Monitor renal function and electrolytes regularly due to risk of hypotension, hyperkalemia, and hyponatremia. Avoid use in patients with anuria or severe renal impairment (e GFR <30 m L/min). Chlorthalidone may exacerbate gout and hyperuricemia. Use caution in patients with hepatic impairment or diabetes.
Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment.
Take this medication exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by your doctor.,Drink plenty of fluids unless otherwise directed by your healthcare provider.,Report symptoms of low blood pressure (dizziness, fainting), electrolyte imbalance (muscle cramps, weakness), or kidney problems (decreased urination).,This drug may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Tell your doctor if you are pregnant or planning to become pregnant; this drug can cause fetal harm.,Limit alcohol intake as it may worsen side effects.,Do not stop taking this medication abruptly without consulting your doctor.
Take once daily at the same time each day with or without food.,Avoid becoming dehydrated; drink adequate fluids unless directed otherwise.,Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs.,Do not take with aliskiren if you have diabetes or renal impairment.,Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness.,May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you.,Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor.,Do not stop taking the medication without talking to your doctor.
No interactions on record
"The combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to a significant reduction in the antihypertensive and cardioprotective effects of azilsartan. NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis, which diminishes the vasodilatory and natriuretic actions that support blood pressure control mediated by ARBs. This interaction may result in loss of blood pressure control, increased risk of renal impairment (especially in volume-depleted or elderly patients), and potential antagonism of the renal protective effects of ARBs in conditions like heart failure or chronic kidney disease."
"Oxprenolol, a non-selective beta-blocker, may attenuate the compensatory sympathetic response to Azilsartan medoxomil-induced hypotension, potentially leading to an excessive drop in blood pressure. This combination can also result in reduced cardiac output due to additive negative chronotropic effects, increasing the risk of bradycardia and heart block. Clinically, patients may experience severe hypotension, dizziness, syncope, or exacerbated heart failure symptoms."
"The combination of timolol, a non-selective beta-blocker, with azilsartan medoxomil, an angiotensin II receptor blocker (ARB), may lead to an increased risk of hypotension, bradycardia, and additive antihypertensive effects. Timolol can antagonize the compensatory sympathetic response to azilsartan-induced vasodilation, potentially resulting in excessive blood pressure reduction. Additionally, both drugs can affect renal perfusion, raising the risk of renal impairment in susceptible patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBYCLOR vs AZILSARTAN MEDOXOMIL, answered by our medical review team.
EDARBYCLOR is a Angiotensin II Receptor Blocker/Thiazide Diuretic Combination that works by EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.. AZILSARTAN MEDOXOMIL is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBYCLOR and AZILSARTAN MEDOXOMIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBYCLOR is: One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.. The standard adult dose of AZILSARTAN MEDOXOMIL is: 40 mg orally once daily. May increase to 80 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBYCLOR and AZILSARTAN MEDOXOMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBYCLOR is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal renal dysplasia, oligohydramnios, and skull ossification defects when used in the secon. AZILSARTAN MEDOXOMIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.